Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer-blinded head-to-head trial.
G HolzerM HokeS Sabeti-SandorT PerkmannA RauscherB StrasseggerSonja RadakovicA TanewPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2020)
In our study, both treatments were documented to exert effects on the cardiovascular system. While adalimumab showed anti-inflammatory effects and improved FMD, FAE interacted favourably with the cholesterol metabolism.
Keyphrases
- cardiovascular risk factors
- end stage renal disease
- rheumatoid arthritis
- newly diagnosed
- study protocol
- chronic kidney disease
- juvenile idiopathic arthritis
- cardiovascular disease
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- type diabetes
- hidradenitis suppurativa
- ulcerative colitis
- phase iii
- atopic dermatitis